» Articles » PMID: 27647907

Optimal Activation of Fc-mediated Effector Functions by Influenza Virus Hemagglutinin Antibodies Requires Two Points of Contact

Overview
Specialty Science
Date 2016 Sep 21
PMID 27647907
Citations 88
Authors
Affiliations
Soon will be listed here.
Abstract

Influenza virus strain-specific monoclonal antibodies (mAbs) provide protection independent of Fc gamma receptor (FcγR) engagement. In contrast, optimal in vivo protection achieved by broadly reactive mAbs requires Fc-FcγR engagement. Most strain-specific mAbs target the head domain of the viral hemagglutinin (HA), whereas broadly reactive mAbs typically recognize epitopes within the HA stalk. This observation has led to questions regarding the mechanism regulating the activation of Fc-dependent effector functions by broadly reactive antibodies. To dissect the molecular mechanism responsible for this dichotomy, we inserted the FLAG epitope into discrete locations on HAs. By characterizing the interactions of several FLAG-tagged HAs with a FLAG-specific antibody, we show that in addition to Fc-FcγR engagement mediated by the FLAG-specific antibody, a second intermolecular bridge between the receptor-binding region of the HA and sialic acid on effector cells is required for optimal activation. Inhibition of this second molecular bridge, through the use of an F(ab') or the mutation of the sialic acid-binding site, renders the Fc-FcγR interaction unable to optimally activate effector cells. Our findings indicate that broadly reactive mAbs require two molecular contacts to possibly stabilize the immunologic synapse and potently induce antibody-dependent cell-mediated antiviral responses: (i) the interaction between the Fc of a mAb bound to HA with the FcγR of the effector cell and (ii) the interaction between the HA and its sialic acid receptor on the effector cell. This concept might be broadly applicable for protective antibody responses to viral pathogens that have suitable receptors on effector cells.

Citing Articles

Cross-Reactive Fc-Mediated Antibody Responses to Influenza HA Stem Region in Human Sera Following Seasonal Vaccination.

Nishiyama A, Nogimori T, Masuta Y, Matsuura T, Kase T, Kondo K Vaccines (Basel). 2025; 13(2).

PMID: 40006687 PMC: 11860798. DOI: 10.3390/vaccines13020140.


Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine.

Casazza J, Hofstetter A, Costner P, Holman L, Hendel C, Widge A NPJ Vaccines. 2024; 9(1):171.

PMID: 39289377 PMC: 11408684. DOI: 10.1038/s41541-024-00959-0.


Fc-FcγR interactions during infections: From neutralizing antibodies to antibody-dependent enhancement.

Edgar J, Bournazos S Immunol Rev. 2024; 328(1):221-242.

PMID: 39268652 PMC: 11659939. DOI: 10.1111/imr.13393.


Flu-COVID combo recombinant protein vaccines elicited protective immune responses against both influenza and SARS-CoV-2 viruses infection.

Huang Y, Shi H, Forgacs D, Ross T Vaccine. 2024; 42(5):1184-1192.

PMID: 38296701 PMC: 11157428. DOI: 10.1016/j.vaccine.2023.12.084.


Vaccine-induced neutralizing antibody responses to seasonal influenza virus H1N1 strains are not enhanced during subsequent pandemic H1N1 infection.

Mooij P, Mortier D, Aartse A, Murad A, Correia R, Roldao A Front Immunol. 2023; 14:1256094.

PMID: 37691927 PMC: 10484506. DOI: 10.3389/fimmu.2023.1256094.


References
1.
Moran T, Monestier M, Lai A, Norton G, Reale M, Thompson M . Characterization of variable-region genes and shared crossreactive idiotypes of antibodies specific for antigens of various influenza viruses. Viral Immunol. 1987; 1(1):1-12. DOI: 10.1089/vim.1987.1.1. View

2.
Friesen R, Lee P, Stoop E, Hoffman R, Ekiert D, Bhabha G . A common solution to group 2 influenza virus neutralization. Proc Natl Acad Sci U S A. 2013; 111(1):445-50. PMC: 3890827. DOI: 10.1073/pnas.1319058110. View

3.
Neumann E, Moser R, Snyers L, Blaas D, Hewat E . A cellular receptor of human rhinovirus type 2, the very-low-density lipoprotein receptor, binds to two neighboring proteins of the viral capsid. J Virol. 2003; 77(15):8504-11. PMC: 165241. DOI: 10.1128/jvi.77.15.8504-8511.2003. View

4.
DiLillo D, Palese P, Wilson P, Ravetch J . Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J Clin Invest. 2016; 126(2):605-10. PMC: 4731186. DOI: 10.1172/JCI84428. View

5.
Medina-Contreras O, Geem D, Laur O, Williams I, Lira S, Nusrat A . CX3CR1 regulates intestinal macrophage homeostasis, bacterial translocation, and colitogenic Th17 responses in mice. J Clin Invest. 2011; 121(12):4787-95. PMC: 3226003. DOI: 10.1172/JCI59150. View